Evidence map›Paper›PMID 27217537›Full record

Trial reportThe Journal of experimental medicine2016

Interferon-driven alterations of the host's amino acid metabolism in the pathogenesis of typhoid fever.

Christoph J Blohmke, Thomas C Darton, Claire Jones, Nicolas M Suarez, Claire S Waddington, Brian Angus, Liqing Zhou, Jennifer Hill, Simon Clare, Leanne Kane and 17 more

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in The Journal of experimental medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
7.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 50 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Typhoid fever.Nature reviews. Disease primers · 2023
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. The Current Status of Enteric Fever Diagnostics and Implications for Disease Control.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 3 countries.

Christoph J BlohmkeOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7LE, England, UK christoph.blohmke@paediatrics.ox.ac.uk.ORCID 0000-0002-1453-9651
Thomas C DartonOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7LE, England, UK.ORCID 0000-0003-2209-9956
Claire JonesOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7LE, England, UK.
Nicolas M SuarezCenter for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH 43210.ORCID 0000-0001-8429-8374
Claire S WaddingtonOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7LE, England, UK.
Brian AngusNuffield Department of Medicine, University of Oxford, OX1 2JD, England, UK.ORCID 0000-0003-3598-7784
Liqing ZhouOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7LE, England, UK.
Jennifer HillMicrobial Pathogenesis Group, The Wellcome Trust Sanger Institute, Hinxton CB10 1SA, England, UK.
Simon ClareMicrobial Pathogenesis Group, The Wellcome Trust Sanger Institute, Hinxton CB10 1SA, England, UK.
Leanne KaneMicrobial Pathogenesis Group, The Wellcome Trust Sanger Institute, Hinxton CB10 1SA, England, UK.ORCID 0000-0002-2241-8120
Subhankar MukhopadhyayMicrobial Pathogenesis Group, The Wellcome Trust Sanger Institute, Hinxton CB10 1SA, England, UK.
Fernanda SchreiberMicrobial Pathogenesis Group, The Wellcome Trust Sanger Institute, Hinxton CB10 1SA, England, UK.
Maria A Duque-CorreaMicrobial Pathogenesis Group, The Wellcome Trust Sanger Institute, Hinxton CB10 1SA, England, UK.ORCID 0000-0002-0567-0412
James C WrightProteomic Mass Spectrometry, The Wellcome Trust Sanger Institute, Hinxton CB10 1SA, England, UK.ORCID 0000-0001-6950-4328
Theodoros I RoumeliotisProteomic Mass Spectrometry, The Wellcome Trust Sanger Institute, Hinxton CB10 1SA, England, UK.
Lu YuProteomic Mass Spectrometry, The Wellcome Trust Sanger Institute, Hinxton CB10 1SA, England, UK.
Jyoti S ChoudharyProteomic Mass Spectrometry, The Wellcome Trust Sanger Institute, Hinxton CB10 1SA, England, UK.ORCID 0000-0003-0881-5477
Asuncion MejiasCenter for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH 43210.ORCID 0000-0002-5983-8006
Octavio RamiloCenter for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH 43210.
Milensu ShanyindeNuffield Department of Primary Care Health Sciences, University of Oxford, OX1 2JD, England, UK.ORCID 0000-0003-4842-9247
Marcelo B SzteinCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201.
Robert A KingsleyMicrobial Pathogenesis Group, The Wellcome Trust Sanger Institute, Hinxton CB10 1SA, England, UK.
Stephen LockhartEmergent Product Development UK, Emergent BioSolutions, Wokingham RG41 5TU, England, UK.ORCID 0000-0002-0805-2193
Myron M LevineCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201.
David J LynnEMBL Australia Group, South Australian Health and Medical Research Institute, North Terrace, Adelaide, SA 5000, Australia School of Medicine, Flinders University, Bedford Park, SA 5042, Australia.ORCID 0000-0003-4664-1404
Gordon DouganMicrobial Pathogenesis Group, The Wellcome Trust Sanger Institute, Hinxton CB10 1SA, England, UK.ORCID 0000-0003-0022-965X
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford OX3 7LE, England, UK.ORCID 0000-0001-7361-719X
Wellcome Sanger Institute · GBUniversity of Oxford · GBNationwide Children's Hospital · USUniversity of Maryland, Baltimore · USEmergent BioSolutions (United Kingdom) · GBFlinders University · AU

Funding

Targeting Dendritic Cells for Enhanced Musocal ImmunityU19AI057234 · NIAID · BAYLOR RESEARCH INSTITUTE · PI SEKALY, RAFICK PIERRE · 2003 to 2013
$49.2M
Wild-type S. typhi Infection in Humans: Integrated Immunoprotective MechanismsU19AI082655 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI FASANO, ALESSIO · 2009 to 2018
$27.8M
Shigella Live Vector-Based Multivalent VaccineU19AI109776 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LEVINE, MYRON MAX · 2014 to 2018
$25.4M
Vaccine Induced Activation of T Follicular Helper Cell SubsetsU19AI089987 · NIAID · BAYLOR RESEARCH INSTITUTE · PI PASCUAL, MARIA VIRGINIA · 2010 to 2015
$17.0M
IMMUNE MECHANISMS OF PROTECTION IN S TYPHI VACCINESR01AI036525 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1994 to 2026
$12.2M
Development of stable and rapidly acting adjuvanted vaccines for biodefenseU01AI082210 · NIAID · SOLIGENIX, INC. · PI BREY, ROBERT N. · 2009 to 2013
$9.1M
Medical Research Council MR/M02637X/1NIAID NIH HHS R01 AI036525NIAID NIH HHS U01 AI082210NIAID NIH HHS U19 AI057234NIAID NIH HHS U19 AI082655NIAID NIH HHS U19 AI089987NIAID NIH HHS U19 AI109776Wellcome Trust 092661
6 · The paper itself

Abstract

Enteric fever, caused by Salmonella enterica serovar Typhi, is an important public health problem in resource-limited settings and, despite decades of research, human responses to the infection are poorly understood. In 41 healthy adults experimentally infected with wild-type S. Typhi, we detected significant cytokine responses within 12 h of bacterial ingestion. These early responses did not correlate with subsequent clinical disease outcomes and likely indicate initial host-pathogen interactions in the gut mucosa. In participants developing enteric fever after oral infection, marked transcriptional and cytokine responses during acute disease reflected dominant type I/II interferon signatures, which were significantly associated with bacteremia. Using a murine and macrophage infection model, we validated the pivotal role of this response in the expression of proteins of the host tryptophan metabolism during Salmonella infection. Corresponding alterations in tryptophan catabolites with immunomodulatory properties in serum of participants with typhoid fever confirmed the activity of this pathway, and implicate a central role of host tryptophan metabolism in the pathogenesis of typhoid fever.

Indexed as

ImmunomodulationAdultFemaleHumansInterferon-gammaInterferon Type IMaleMiddle AgedSalmonella typhiTryptophanTyphoid FeverInterferon-gammaInterferon Type ITryptophan

Identifiers

PMID27217537
PMCPMC4886356
OpenAlexW2398199165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.